SCHEMBL6991010

SCHEMBL6991010

Cc1ccc2c(c1)Nc1sc3ccccc3c1C(N1CCN(C)CC1)=N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.53
DRD4 P21917 5/20 0.53
CHRM1 P11229 5/20 0.53
CHRM2 P08172 3/20 0.53
CHRM4 P08173 3/20 0.53
CHRM5 P08912 3/20 0.53
ADRA2A P08913 3/20 0.53
ADRA2B P18089 3/20 0.53
ADRA2C P18825 3/20 0.53
CHRM3 P20309 3/20 0.53
DRD1 P21728 3/20 0.53
ADRA1D P25100 3/20 0.53
HTR2A P28223 3/20 0.53
HTR2C P28335 3/20 0.53
ADRA1A P35348 3/20 0.53
HRH1 P35367 3/20 0.53
ADRA1B P35368 3/20 0.53
HTR2B P41595 3/20 0.53
KCNH2 Q12809 3/20 0.53
DRD3 P35462 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6990101 0.92 CHRM1 (0.53) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6998224 0.89 DRD2 (0.53) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6990220 0.89 CHRM1 (0.49) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6993087 0.89 CHRM1 (0.49) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6998870 0.88 CHRM1 (0.60) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6995640 0.88 DRD2 (0.61) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6990005 0.88 DRD2 (0.61) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6996709 0.87 CHRM1 (0.46) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6998262 0.85 CHRM1 (0.47) DRD2DRD4CHRM1CHRM2CHRM4
SCHEMBL6998395 0.85 CHRM1 (0.47) DRD2DRD4CHRM1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP claimed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US claimed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT DRD2 620/4885DRD4 107/4885CHRM1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.